COVID-19 Vaccination in Patients with Severe Asthma on Biologic Treatment: Safety, Tolerability, and Impact on Disease Control.
Pfizer mRNA SARS-CoV-2/COVID 19 vaccine
biologics
quality of life
safety
severe asthma
tolerability
Journal
Vaccines
ISSN: 2076-393X
Titre abrégé: Vaccines (Basel)
Pays: Switzerland
ID NLM: 101629355
Informations de publication
Date de publication:
04 Aug 2021
04 Aug 2021
Historique:
received:
11
07
2021
revised:
02
08
2021
accepted:
02
08
2021
entrez:
28
8
2021
pubmed:
29
8
2021
medline:
29
8
2021
Statut:
epublish
Résumé
COVID-19 vaccination has been recommended for severe asthmatics. We aimed to evaluate the safety, tolerability, and impact on disease control and patient's quality of life of the mRNA SARS-CoV-2/COVID-19 vaccine in severe asthma patients regarding biologic treatment. Severe asthmatic patients regularly managed by two big allergy and respiratory referral centers were offered to undergo Pfizer COVID 19 vaccination at the hospital site. Patients filled in an adverse events questionnaire after the first and second dose, as well as the Asthma Control Test (ACT) and Asthma Quality of Life Questionnaire (AQLQ). Overall, 253 patients were vaccinated; only 16 patients refused. No serious events were detected. Less than 20% of patients reported side effects, most of which were classified as very common side effects. No differences were reported according to the ongoing biologic drug. A significant improvement in both ACT and AQLQ was observed between the first and the second dose administration. Our data confirm the optimal safety and tolerability profile of mRNA SARS- CoV-2/COVID-19 in severe asthma patients on biologic treatment, as well as their positive attitude towards COVID-19 vaccination. The negligible proportion of patients reporting side effects and the absence of asthma exacerbations are relevant to support the COVID-19 vaccination campaign in severe asthma patients worldwide.
Sections du résumé
BACKGROUND
BACKGROUND
COVID-19 vaccination has been recommended for severe asthmatics. We aimed to evaluate the safety, tolerability, and impact on disease control and patient's quality of life of the mRNA SARS-CoV-2/COVID-19 vaccine in severe asthma patients regarding biologic treatment.
METHODS
METHODS
Severe asthmatic patients regularly managed by two big allergy and respiratory referral centers were offered to undergo Pfizer COVID 19 vaccination at the hospital site. Patients filled in an adverse events questionnaire after the first and second dose, as well as the Asthma Control Test (ACT) and Asthma Quality of Life Questionnaire (AQLQ).
RESULTS
RESULTS
Overall, 253 patients were vaccinated; only 16 patients refused. No serious events were detected. Less than 20% of patients reported side effects, most of which were classified as very common side effects. No differences were reported according to the ongoing biologic drug. A significant improvement in both ACT and AQLQ was observed between the first and the second dose administration.
CONCLUSIONS
CONCLUSIONS
Our data confirm the optimal safety and tolerability profile of mRNA SARS- CoV-2/COVID-19 in severe asthma patients on biologic treatment, as well as their positive attitude towards COVID-19 vaccination. The negligible proportion of patients reporting side effects and the absence of asthma exacerbations are relevant to support the COVID-19 vaccination campaign in severe asthma patients worldwide.
Identifiants
pubmed: 34451978
pii: vaccines9080853
doi: 10.3390/vaccines9080853
pmc: PMC8402597
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Allergy. 2021 Mar;76(3):871-874
pubmed: 32716580
Eur Respir J. 2021 Mar 4;57(3):
pubmed: 33154029
Allergy. 2021 Mar;76(3):957-958
pubmed: 32767400
World Allergy Organ J. 2021 Feb;14(2):100517
pubmed: 33558825
Eur Respir J. 2021 Mar 4;57(3):
pubmed: 32978309
Eur Respir J. 2014 Feb;43(2):343-73
pubmed: 24337046
Vaccines (Basel). 2021 Jan 11;9(1):
pubmed: 33440794
Ann Rheum Dis. 2021 Feb 9;:
pubmed: 33563595
Vaccine. 2021 Mar 26;39(13):1812-1817
pubmed: 33678452
Respir Med. 2021 Jan;176:106261
pubmed: 33260107
Allergo J Int. 2021 Apr 19;:1-17
pubmed: 33898162
World Allergy Organ J. 2020 May 16;13(5):100126
pubmed: 32426090
Vaccine. 2021 Feb 5;39(6):865-867
pubmed: 33441235
Vaccines (Basel). 2021 Apr 14;9(4):
pubmed: 33919672
J Am Acad Dermatol. 2019 Jan;80(1):158-167.e1
pubmed: 30092324
Allergol Select. 2021 Apr 1;5:140-147
pubmed: 33842829
J Asthma Allergy. 2018 Nov 20;11:181-192
pubmed: 30510434